You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Split-course hypofractionated concurrent chemoradiotherapy

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Esophageal Squamous Cell Carcinoma Trial in Guangzhou (Split-course hypo-CCRT, Induction chemo-immunotherapy, Concurrent chemo)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Split-course hypo-CCRT
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Aug 26, 2023

Lung Tumors Trial (Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy), Envafolimab combined

Not yet recruiting
  • Lung Neoplasms
  • Envafolimab combined with concurrent chemoradiotherapy (Hypofractionated radiotherapy)
  • Envafolimab combined with concurrent chemoradiotherapy (Conventional Radiotherapy)
  • (no location specified)
Jun 12, 2023

NSCLC Trial in Guangzhou (chest radiation, concurrent chemo, Methylprednisolone)

Terminated
  • Non-small Cell Lung Cancer
  • chest radiation
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Nov 25, 2022

Diffuse Midline Glioma, H3 K27M-Mutant Trial in Rochester (Hypofractionated Radiation Therapy, Quality-of-Life Assessment,

Recruiting
  • Diffuse Midline Glioma, H3 K27M-Mutant
  • Hypofractionated Radiation Therapy
  • +2 more
  • Rochester, Minnesota
    Mayo Clinic in Rochester
Jan 6, 2023

Pancreatic Carcinoma Trial in Nanjing (Tislelizumab, Gemcitabine, Nab paclitaxel)

Recruiting
  • Pancreatic Carcinoma
  • Nanjing, Jiangsu, China
    The Affiliated Nanjing Drum Tower Hospital of Nanjing University
Dec 1, 2022

NSCLC Trial in Guangzhou (split-course radiotherapy, concurrent chemo)

Active, not recruiting
  • Non-small Cell Lung Cancer
  • split-course radiotherapy
  • concurrent chemotherapy
  • Guangzhou, China
    Sun Yat-sen University
Nov 25, 2022

Locally Advanced Rectal Carcinoma Trial (Short course radiotherapy with concurrent capecitabine(825mg/m2), Long course

Not yet recruiting
  • Locally Advanced Rectal Carcinoma
  • Short course radiotherapy with concurrent capecitabine(825mg/m2)
  • Long course radiotherapy with concurrent capecitabine(825mg/m2)
  • (no location specified)
Jun 24, 2023

NSCLC Trial in Guangzhou (Hypofractionated radiotherapy, induction chemo-immunotherapy, concurrent chemo)

Recruiting
  • Non-small Cell Lung Cancer
  • Hypofractionated radiotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun yat-sen university cancer center
Nov 14, 2023

Glioblastoma, Newly Diagnosed Glioblastoma Trial in Stanford (device, drug, radiation)

Recruiting
  • Glioblastoma
  • Newly Diagnosed Glioblastoma
  • Optune
  • +3 more
  • Stanford, California
    Stanford University
Aug 1, 2022

Locally Advanced Lung Carcinoma Trial in Guangzhou (Concurrent chemo and single radiation dose climbing)

Recruiting
  • Locally Advanced Lung Carcinoma
  • Concurrent chemotherapy and single radiation dose climbing
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Jul 11, 2021

Esophageal Tumors, Adverse Drug Event Trial in Nanjing (dietary supplement, drug, radiation)

Recruiting
  • Esophageal Neoplasms
  • Adverse Drug Event
  • Nutritional Support Team
  • +3 more
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Mar 23, 2023

Thymoma and Thymic Carcinoma Trial in Guangzhou (Thymosin a1, hypofractionated radiotherapy, concurrent chemoradiotherapy)

Active, not recruiting
  • Thymoma and Thymic Carcinoma
  • Thymosin a1
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Nov 27, 2021

Nasopharyngeal Carcinoma, De-escalation Therapy Trial in Guangzhou (Cisplatin-based induction chemo, Full course of PD-1/PD-L1

Recruiting
  • Nasopharyngeal Carcinoma
  • De-escalation Therapy
  • Cisplatin-based induction chemotherapy
  • +4 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Oct 16, 2023

NSCLC Trial in Guangzhou (split-course radiotherapy, concurrent chemo)

Unknown status
  • Non-small Cell Lung Cancer
  • split-course radiotherapy
  • concurrent chemotherapy
  • Guangzhou, Guangdong, China
    Hui Liu
Jan 15, 2021

Head and Neck Squamous Cell Carcinoma Trial in Villejuif, Monaco (Standard RT, Hypofractionated RT)

Completed
  • Head and Neck Squamous Cell Carcinoma
  • Standard RT
  • Hypofractionated RT
  • Villejuif, France
  • +1 more
Apr 8, 2021

NSCLC Trial in Guangzhou (Concurrent chemo, split-course radiotherapy, thymosin alpha 1)

Completed
  • Non-small Cell Lung Cancer
  • Concurrent chemotherapy
  • +2 more
  • Guangzhou, Guangdong, China
    Sun yat-sen University Cancer Center
Dec 30, 2021

Esophageal Cancer Trial (Hypofractionated radiotherapy)

Not yet recruiting
  • Esophageal Cancer
  • Hypofractionated radiotherapy
  • (no location specified)
Jan 18, 2023

Rectal Cancer Trial in Beijing (combination product, radiation, drug, procedure)

Recruiting
  • Rectal Cancer
  • Concurrent Chemoradiotherapy Radiotherapy
  • +5 more
  • Beijing, China
    Department of Radiation Oncology, Cancer Institute and Hospital,
Jun 6, 2021

NSCLC Trial in Guangzhou (split-course radiotherapy, Concurrent chemo)

Completed
  • Non-small Cell Lung Cancer
  • split-course radiotherapy
  • Concurrent chemotherapy
  • Guangzhou, Guangdong, China
    Hui Liu
Apr 10, 2020

NSCLC, NSCLC Stage III, Recurrent Non Small Cell Lung Cancer Trial (Garmin Vivofit Activity Tracker)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • +2 more
  • Garmin Vivofit Activity Tracker
  • (no location specified)
Aug 31, 2022

Esophageal Cancer, Intensity-modulated Radiation Therapy, Concurrent Chemoradiotherapy Trial in Beijing (rhTPO)

Not yet recruiting
  • Esophageal Cancer
  • +3 more
  • Beijing, Beijing, China
    Department of Radiation Oncology, Cancer Institute and Hospital,
Jul 12, 2023

Envafolimab Combined With Endostar and Concurrent

Not yet recruiting
  • Cervical Cancer
  • (no location specified)
May 19, 2023

Nasopharyngeal Carcinoma Trial in Shanghai (Radiotherapy, Cisplatin)

Recruiting
  • Nasopharyngeal Carcinoma
  • Shanghai, Shanghai, China
    Fudan Universtiy Shanghai Cancer Centre
Jan 7, 2023

Locally Advanced Rectal Cancer Trial in Beijing (Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor), Long-course

Recruiting
  • Locally Advanced Rectal Cancer
  • Long-course chemoradiation, with Tislelizumab (PD-1 inhibitor)
  • Long-course chemoradiation, without Tislelizumab (PD-1 inhibitor)
  • Beijing, Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 25, 2023

Cervical Cancer Trial in Chongqing (Autologous blood transfusion with haematopoietic stem cells)

Recruiting
  • Cervical Cancer
  • Autologous blood transfusion with haematopoietic stem cells
  • Chongqing, Chongqing, China
    Chongqing University Cancer Hospital
Sep 13, 2022